CALCOL INC.(CLCL-OTC)RETURNS TO MEDICAL MARIJUANA ROOTS
CALCOL INC. (CLCL-OTC): RETURNING TO OUR ROOTS IN MEDICAL MARIJUANA
Twenty six years ago, on October 19, 1988, the Wall Street Journal reported
“CALCOL ENTERS ACCORD TO SELL A NAUSEA DRUG WITH THC”, that CALCOL INC. (CLCL-OTC) had licensed the distribution rights on a non-exclusive basis for 15 years (until 2003) to Barr Laboratories Inc. for our chemically synthetic medical marijuana product Delta-9-Tetrahydrocannabinol (THC). The THC drug, produced for us in Europe by a division of a major pharmaceutical company, was for the treatment of nausea in cancer patients suffering the side effects of chemotherapy.
After 26 years, we are proud that our company CALCOL INC. (CLCL-OTC) has retained the manufacturing rights to our method of production of large scale good GMP pharmaceutical grade THC and CBD, and with the distribution rights returned to us, and with this important medicine now widely accepted by both the medical community, the US government, and the American public, and in such great demand, we have returned to our roots as a THC pharmaceutical company. We are once again working in the field of research and development of methods of administration of THC and CBD for the clinical treatment of human sickness and disease, through various formulations and medical devices, and we are once again working with world renowned chemists, pharmacologists, neurologists, psychopharmacologists, oncologists, as well as patent lawyers and FDA regulatory experts in the field of THC research, who have been our friends, scientific advisors, scientific collaborators, and research colleagues for so many years.
It is our objective to work together again with our friends and colleagues to try to develop precise basic research and if possible clinical trials of various forms, formulations and methods of administration of THC and CBD for the welfare of suffering humanity. While our principal business for most of the last twenty years has been soft drinks, MALIBU-COLA in China, and globally trademarked energy drinks KULONG FRUIT FLAVORED VITAMIN DRINK for production and sale in China, KULONG VITAMIN ENRICHED ENERGY DRINK made in the USA, and for distribution worldwide, we are happy to be able to once again make a contribution to public health in pharmaceutical research and development of what we hope will be a more perfect form of THC and CBD for treatment of human sickness and disease.
Some of the diseases and syndromes we hope to address through clinical trials in the future include nausea from chemotherapy in cancer and AIDS patients, multiple sclerosis, PTSD, Parkinson’s disease and tremor, alcohol and drug withdrawal syndrome, schizophrenia and psychosis, epilepsy and seizure disorders refractory to other medications, metastatic cancer, anorexia/bulimia, peripheral neuropathy and other pain, glaucoma, and many other illnesses.
I am proud personally to have been cited in the US Congressional Record more than 30 years ago for my contributions to medical marijuana research (“ONE MORE STEP FOR MEDICAL MARIJUANA”, Letter to the Editor, The New York Times, by Norman C Kaplan, published September 6, 1983); to have published three scientific papers and one abstract ( “Profile of THC-Mustard”, N.C. Kaplan, P L Salk, Salk Institute Annual Reports 1979, p.145; “Dichloroethyl carbamoyl ester of Delta-9-THC”, N.C. Kaplan, Scientia Sinica Series B, October 1984,27:1048-1058, “Pharmacological profile of Delta-9-THC Carbamate”, P.J. Little, N.C. Kaplan, B.R. Martin, Alcohol and Drug Research 1987, 7 (5-6),517-23 ) and one patent in this field
US Patent 4,327,028, “THC-Mustard”, Norman C. Kaplan, CALCOL INC. April 27, 1982; and to have been the founder and CEO of one of the first two companies CALCOL INC. (CLCL-OTC) to have developed THC for human use.
This is not an offer to buy or sell securities. CALCOL INC. common stock (par value $.001) trades OTC in the United States under the symbol “CLCL”, involves a high degree of risk, and is a suitable investment only for accredited, institutional and overseas investors who are able to assess the risk and can afford the loss of their entire investment. This note may contain certain “forward looking” statements, and should not be relied upon in any investment decision.
Thank you. Happy Hanukah, Merry Christmas, Happy New Year. And Sing Nie Qiao Lo (Happy Chinese New Year). Norman C. Kaplan, Chairman and President, CALCOL INC. December 23, 2014. Beijing, China and Cleveland, Ohio USA.
